Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9541107 | 0.96 | LMNA (0.39) | LMNATHRB | |
| SCHEMBL64875 | 0.92 | LMNA (0.41) | LMNATHRBCA2 | |
| SCHEMBL6278209 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1169605 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL28699116 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL4937641 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| Perflisopent SCHEMBL1509322 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL28701223 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL7626574 | 0.88 | LMNA (0.47) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1271519 | 0.88 | LMNA (0.35) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334872-A1 | SEMI-SYNTHESIS PROCEDURES | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | claimed |
| EP-3209642-A1 | SEMI-SYNTHESIS PROCEDURES | Tetraphase Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | claimed |
| CN-107108472-A | Semi-synthesis process | 四相制药公司 | 2017-08-29 | — | — | CN | claimed |
| US-10618879-B2 | Semi-synthesis procedures | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| CN-107108472-B | Semi-synthesis process | 四相制药公司 | 2020-03-13 | — | — | CN | disclosed |
| US-20190210988-A1 | SEMI-SYNTHESIS PROCEDURES | TETRAPHASE PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10087157-B2 | Semi-synthesis procedures | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| CN-108602995-A | Flame-retardant polyolefin resin composition | 株式会社艾迪科 | 2018-09-28 | — | — | CN | disclosed |
| EP-2993710-B1 | ULTRAVIOLET LIGHT-EMITTING DEVICE | SOKO KAGAKU CO LTD (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-9972758-B2 | Ultraviolet light emitting device | SOKO KAGAKU CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2400515-B1 | PROCESS FOR MANUFACTURING ELECTRET, AND ELECTROSTATIC INDUCTION-TYPE CONVERSION ELEMENT | ASAHI GLASS CO LTD (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-7359118-B2 | Method for producing mold for use in duplicating light diffusion sheet, light diffusion sheet and method for producing the same, and screen | SONY CORPORATION (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20060103929-A1 | Screen and its manufacturing method | SONY CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1630596-A1 | SCREEN AND ITS MANUFACTURING METHOD | Sony Corporation (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-20050184412-A1 | Method for producing mold for use in duplicating light diffusion sheet, light diffusion sheet and method for producing the same, and screen | SONY CORPORATION (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1564587-A1 | Method for producing mold for use in duplicating light diffusion sheet, light diffusion sheet and method for producing the same, and screen | SONY CORPORATION (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-RE37022-E1 | A FLUORINE CONTAINING POLYMER COMPRISING A POLYMER HAVING A FUNCTIONAL GROUP AND A FLUORINE-CONTAINING ALIPHATIC CYCLIC STRUCTURE DISSOLVED IN A SOLVENT MIXTURE OF AN APROTIC AND PROTIC FLUORINE-CONTAINING SOLVENTS | ASAHI GLASS COMPANY LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5498657-A | ALIPHATIC CYCLIC STRUCTURE | ASAHI GLASS COMPANY LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5318996-A | Blowing with mixture of water, chlorodifluoromethane dichlorofluoroethane and perfluorinated hydrocarbons | BASF CORPORATION (US) | 1994-06-07 | — | — | US | disclosed |
| WO-1993005200-A1 | AZEOTROPE-LIKE COMPOSITIONS OF 1,1-DICHLORO-1-FLUOROETHANE AND PERFLUOROCARBONS AND OPTIONALLY NITROMETHANE | ALLIED-SIGNAL INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334872-A1 | SEMI-SYNTHESIS PROCEDURES | F7, CASP7, TCF7 | LMNA 1054/4885THRB 803/4885CA2 1279/4885 |
| US-20190210988-A1 | SEMI-SYNTHESIS PROCEDURES | F7, TET3, CASP7 | LMNA 1543/4885THRB 1428/4885CA2 1058/4885 |
| US-10087157-B2 | Semi-synthesis procedures | F7, CASP7, TCF7 | LMNA 1132/4885THRB 784/4885CA2 1385/4885 |
| US-10618879-B2 | Semi-synthesis procedures | F7, TET3, CASP7 | LMNA 1543/4885THRB 1428/4885CA2 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.